RT Journal Article
SR Electronic
T1 Radioembolization for Treatment of Salvage Patients with Colorectal Cancer Liver Metastases: A Systematic Review
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1890
OP 1895
DO 10.2967/jnumed.113.119545
VO 54
IS 11
A1 Charlotte E.N.M. Rosenbaum
A1 Helena M. Verkooijen
A1 Marnix G.E.H. Lam
A1 Maarten L.J. Smits
A1 Miriam Koopman
A1 Tom van Seeters
A1 Malou A. Vermoolen
A1 Maurice A.A.J. van den Bosch
YR 2013
UL http://jnm.snmjournals.org/content/54/11/1890.abstract
AB Currently, there is no consensus on the use of 90Y radioembolization for salvage patients with colorectal cancer liver metastases. The purpose of this study was to provide a comprehensive overview of the available data on tumor response and survival after 90Y radioembolization for this group of patients. Methods: A systematic literature search was conducted in PubMed (Medline), Excerpta Medica (EMBASE), and the Cochrane Library (September 2012) with synonyms for “radioembolization” and “colorectal cancer liver metastases.” Results were described separately for patient cohorts treated with 90Y radioembolization as monotherapy and with 90Y radioembolization in combination with chemotherapy. Results: The search yielded 13 relevant articles for systematic review on 90Y radioembolization as monotherapy and 13 relevant articles on 90Y radioembolization combined with chemotherapy. Disease control rates (i.e., complete response, partial response, and stable disease) ranged from 29% to 90% for 90Y radioembolization as monotherapy and from 59% to 100% for 90Y radioembolization combined with chemotherapy. Heterogeneity in the data prohibited pooling of response rates. Survival proportions at 12 mo ranged from 37% to 59% for 90Y radioembolization as monotherapy and from 43% to 74% for 90Y radioembolization combined with chemotherapy. Conclusion: In the studies included in this systematic review, approximately 50% of salvage patients with colorectal cancer liver metastases survive more than 12 mo after treatment with 90Y radioembolization, either as monotherapy or in combination with chemotherapy. Heterogeneity between studies has unfortunately prohibited pooling of data. Future research will discern the precise role of 90Y radioembolization in general clinical practice in comparison with chemotherapy.